Compare CLPS & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | ENLV |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.8M | 26.6M |
| IPO Year | 2018 | 1995 |
| Metric | CLPS | ENLV |
|---|---|---|
| Price | $0.93 | $0.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 26.3K | ★ 11.0M |
| Earning Date | 10-17-2025 | 11-28-2025 |
| Dividend Yield | ★ 14.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $164,481,414.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.17 | N/A |
| 52 Week Low | $0.82 | $0.83 |
| 52 Week High | $1.88 | $2.10 |
| Indicator | CLPS | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 46.57 |
| Support Level | $0.90 | $0.88 |
| Resistance Level | $0.98 | $1.06 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 46.94 | 14.12 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.